Overview

Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Status:
Terminated
Trial end date:
2021-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Criteria
Inclusion Criteria:

1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic
stem cells transplantation.

2. Steroid dependent or refractory classic chronic GVHD disease defined as modified
National Institutes of Health criteria(2014) below at any time post-hematopoietic cell
transplant(post-HCT)

1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater
than or equal to(<=) 0.25mg/kg/day or <=0.5mg/kg every other day(prednisolone
doses) due to recurrence or progression of cGVHD manifestations, it is considered
as steroid-dependent disease if the lowest tapering dose of the second occasion
is equal or higher than the lowest tapering dose of the first occasion

2. Refractory disease, defined as, when cGVHD manifestations progress despite the
use of a regime containing glucocorticoid (prednisolone at >=1mg/kg/day for at
least 1 week) or persist without improvement despite continued treatment with
glucocorticoid (prednisolone at >=0.5mg/kg/day or 1mg/kg every other day) for at
least 4 weeks.

3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at
study entry. The dose of steroids must be stable for 14 days prior to starting
anlotinib.

4. At the time of trial enrollment, participants may be receiving other immunosuppressive
therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for
14 days prior to starting anlotinib.

5. Neutrophil≥1.5×109/L,platelet≥50×109/L

6. Karnofsky or Lansky performance status>=60

7. Participants should sign the agreement.

Exclusion Criteria:

1. Known or suspected active acute GVHD.

2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer
chemotherapy in the 4weeks prior to starting study drug.

3. Concomitant use of warfarin or other Vitamin K antogonists.

4. Known bleeding disorders or hemophilia.

5. Known history of human immunodeficiency virus or active with hepatitis C. virus or
hepatitis B virus.

6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or
antifungal medicine or recent infection requiring systemic treatment .